CGC · Canopy Growth

The thesis

Canopy Growth's operating results are improving, but the shares closed at $0.59 on 10 November 2026, 69.1% below the 52-week high of $1.92, so the market is not paying for that improvement. The judge's recommendation in the DEA rescheduling case and the board's decision on a share consolidation settle the next step.

The second-quarter fiscal 2027 report, filed on 6 November 2026 in Canadian dollars, showed net revenue of C$81.4 million, up 22% from C$66.7 million a year earlier. International cannabis revenue was C$12.3 million, up 141%, driven by Germany and Poland. Free cash outflow was C$15.5 million, against C$25.7 million in the June quarter and C$19.2 million a year earlier.

Net loss still widened by C$35.7 million year over year, mainly from C$35.8 million of fair value charges on assets tied to Canopy USA, according to the company's release. Benzinga reported the shares fell 9.03% to $0.61 on 6 November 2026 after a US-dollar revenue figure of $58.149 million missed a $59.120 million estimate. The shares closed at $0.59 on 10 November 2026.

The story is well known toward exhausted: the rescheduling story is well known, the 5 November 2026 reply briefs have passed without a reported recommendation, and the shares fell from $0.67 on 28 October 2026 to $0.59 across a results report that showed lower cash burn.

Bullish and bearish views on Canopy Growth Corporation

The bull case on Canopy Growth Corporation (CGC), in brief: cash burn fell sharply. The bear case: the shares fall on good operating news.

Bull case

• Cash burn fell sharply. Free cash outflow was C$15.5 million for the quarter ended 30 September 2026, from C$25.7 million for the quarter ended 30 June 2026 (company results release, 6 November 2026).
• International sales more than doubled. International cannabis revenue rose 141% to C$12.3 million, from C$5.1 million, and the Smiths Falls facility received EU GMP (good manufacturing practice) certification, per the company release.
• Management points to positive adjusted EBITDA. The CFO said on 6 November 2026 that Canopy is "within reach of reporting positive adjusted EBITDA during fiscal 2027." Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was a loss of C$2.9 million, against C$3.0 million a year earlier.
• Liquidity exceeds debt in the release. Cash and equivalents were C$247.3 million at 30 September 2026, plus C$72.5 million of short-term investments. The balance sheet lists C$43.1 million of current debt and C$202.7 million of long-term debt.
• The hearing stays closed to new testimony. On 22 October 2026 Judge Julius declined to reopen the rescheduling hearing and admitted the Government Accountability Office report (NORML; Cannabis Business Times).

Bear case

• The shares fall on good operating news. The close was $0.67 on 28 October 2026 and $0.59 on 10 November 2026. The three-month price change is −41.3%.
• Margin slipped. Adjusted gross margin was 31% in the September quarter, down from 33% a year earlier, per the company release. Storz & Bickel device revenue fell 4% to C$15.1 million, according to a Cannabis Business Times summary of the release.
• US-linked assets are being written down. The C$35.8 million of fair value charges on Canopy USA-related assets drove the wider net loss. A third-party earnings summary also cites about $193 million of Acreage and Wana debt in default with a forbearance deadline of 31 January 2027; the company release carries only a general risk factor on that debt.
• A reschedule brings no direct tax relief. Canopy is a Canadian licensed producer, so US Section 280E tax relief does not reach it, and the judge's recommendation has no binding deadline.
• A consolidation is authorized. Shareholders approved a one-for-five to one-for-fifteen consolidation on 23 October 2026, and the shares trade at $0.59. Canopy's one-for-ten consolidation followed a 11 July 2023 Nasdaq deficiency letter.

Price setup

The last adjusted close is $0.59 on 10 November 2026, with a 14-day relative strength index (RSI) of 38.2. On 28 October 2026 the RSI was 20.2, so the latest reading shows some recovery from the extreme level while the price made a lower low.

The thesis is held at the lowest rating, which treats the case as more likely to lag the S&P 500 than to lead it. Operating improvement is on file; a rising share price is not.

The shares trade 69.1% below the $1.92 52-week high. Closes of $0.74 on 15 October 2026, $0.67 on 28 October 2026 and $0.59 on 10 November 2026 form a steady descent. A share price below $1 is also the condition behind the Nasdaq deficiency letter of 2023.

Catalysts ahead

• 30 November 2026 (est.): Judge Julius's recommendation on rescheduling, undated; reply briefs closed 5 November 2026. A recommendation for or against Schedule III is the main sentiment driver for the shares, though it brings no direct tax relief to Canopy.
• 30 November 2026 (est.): Board decision on applying the approved one-for-five to one-for-fifteen share consolidation, undated. The shares trade at $0.59, and a ratio and effective date would show whether the board acts on the 23 October 2026 authorization.
• 31 January 2027: Forbearance deadline on Acreage and Wana debt, as cited by a third-party earnings summary. Canopy USA-related assets already took C$35.8M of fair value charges in the September quarter.

What would change the view

A daily close above $0.6757, the close before the results of 6 November 2026 (5 November 2026), would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

Canopy trades with US cannabis rescheduling news more than with its own Canadian results, which is the link the Cannabis reclassification story rests on. Dual-listing means the Toronto line (WEED) and the Nasdaq line (CGC) move with USD/CAD as well as with the shares. The company reports in Canadian dollars, so US-dollar consensus figures such as the $59.120 million revenue estimate cited by Benzinga will not match the C$81.4 million headline.